乳腺癌pS2蛋白表达的临床意义

目的 探讨乳腺癌pS2蛋白表达与临床病理因素的关系，评估其作为乳腺癌预后判断和内分泌治疗指标的价值。方法 采用免疫组化法检测75例乳腺癌组织中pS2蛋白及雌激素受体(Estrogen receptor，ER)、孕激素受体(Progesterone receptor，PR)的表达，分析pS2蛋白阳性表达与病人年龄、月经状况、肿瘤大小、腋窝淋巴结转移、病理类型和ER、PR的关系。结果 pS2蛋白表达阳性率为33．3％，其表达与病人年龄和病理类型有关，与肿瘤大小无关，绝经前较绝经后、腋窝淋巴结有转移者较无转移者pS2阳性率高，但无统计学差异。pS2蛋白表达与ER、PR有关，但并不完全一致。结论 乳腺癌pS2蛋白的表达与部分临床病理因素有关，能在一定程度上反映病人的预后。pS2阳性表达可能是乳腺癌内分泌治疗的合理指征，但pS2不能取代ER、PR的检测。

Clinical significance of pS2 protein expression in breast cancer

Objective To explore the relationship between the expression of pS2 protein and the clinicopathological parameters in breast cancer and to evaluate the value of pS2 as a prognostic factor for breast carcinoma and a predictive factor for response to endocrine therapy. Methods Expression levels of pS2 protein, estrogen receptor (ER) and progestogen receptor (PR) in tissues from 75 cases of breast cancer were detected by immunohistochemical assay. The relationship of pS2 protein expression with patient age, menopausal status, tumor size, metastasis to the axillary lymph nodes, pathological types, ER and PR was analyzed. Results pS2 protein, expressed in 33.3% of breast carcinomas, was correlated with patient age and pathological types, but was not correlated with tumor size. The positive rate of pS2 protein before menopause was higher than that after menopause, but no significant difference was found. Similarly, higher positive rate of pS2 protein was found in patients with metastasis to axillary lymph nodes than those without, but no significant difference was found. pS2 expression was correlated with ER and PR, but they were not perfectly consistent. Conclusion In breast cancer, pS2 protein expression, associated with some clinical factors and pathological features, is a good prognostic factor. pS2 expression may be a reasonable index for endocrinotherapy of breast carcinoma, but the detection of pS2 protein can not be employed in place of the detection of ER and PR.